The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer

被引：103

作者：

Gomez, Carmen E. ^{[1
]}

Najera, Jose L. ^{[1
]}

Krupa, Magdalena ^{[1
]}

Esteban, Mariano ^{[1
]}

机构：

[1] Ciudad Univ Catablanco, CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Madrid 28049, Spain

来源：

CURRENT GENE THERAPY | 2008年 / 8卷 / 02期

关键词：

D O I：

10.2174/156652308784049363

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Recombinants based on poxviruses have been used extensively as gene delivery systems to study many biological functions of foreign genes and as vaccines against many pathogens, particularly in the veterinary field. Based on safety record, efficient expression and ability to trigger specific immune responses, two of the most promising poxvirus vectors for human use are the attenuated modified vaccinia virus Ankara ( MVA) and the Copenhagen derived NYVAC strains. Because of the scientific and clinical interest in these two vectors, here we review their biological characteristics, with emphasis on virus-host cell interactions, viral immunomodulators, gene expression profiling, virus distribution in animals, and application as vaccines against different pathogens and tumors.

引用

页码：97 / 120

页数：24

共 224 条

[81]

HARROP R, 2007, CANC IMMUNOL IMMUNOT

[82] Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses [J].

Harrop, Richard ;

Drury, Noel ;

Shingler, William ;

Chikoti, Priscilla ;

Redchenko, Irina ;

Carroll, Miles W. ;

Kingsman, Susan M. ;

Naylor, Stuart ;

Melcher, Alan ;

Nicholls, Joanna ;

Wassan, Harpreet ;

Habib, Nagy ;

Anthoney, Alan .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4487-4494

[83] Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial [J].

Harrop, Richard ;

Connolly, Noel ;

Redchenko, Irina ;

Valle, Juan ;

Saunders, Mark ;

Ryan, Matthew G. ;

Myers, Kevin A. ;

Drury, Noel ;

Kingsman, Susan M. ;

Hawkins, Robert E. ;

Carroll, Miles W. .

CLINICAL CANCER RESEARCH, 2006, 12 (11) :3416-3424

[84] The poxvirus protein A52R targets toll-like receptor signaling complexes to suppress host defense [J].

Harte, MT ;

Haga, IR ;

Maloney, G ;

Gray, P ;

Reading, PC ;

Bartlett, NW ;

Smith, GL ;

Bowie, A ;

O'Neill, LAJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (03) :343-351

[85]

Hawkins RE, 2006, J CLIN ONCOL, V24, p460S

[86]

HOCHSTEI.V, 1972, ZENTRALBL BAKTER PAR, V156, P1

[87]

Hodge JW, 2003, CANCER RES, V63, P7942

[88] Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme [J].

Huemer, HP ;

Strobl, B ;

Nowotny, N .

VACCINE, 2000, 18 (14) :1320-1326

[89] Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design [J].

Ibango, Hannah B. ;

Brookes, Roger H. ;

Hill, Philip C. ;

Owiafe, Patrick K. ;

Fletcher, Helen A. ;

Lienhardt, Christian ;

Hill, Adrian V. S. ;

Adegbola, Richard A. ;

McShane, Helen .

LANCET INFECTIOUS DISEASES, 2006, 6 (08) :522-528

[90] VACCINIA VIRUS COMPLEMENT-CONTROL PROTEIN PREVENTS ANTIBODY-DEPENDENT COMPLEMENT-ENHANCED NEUTRALIZATION OF INFECTIVITY AND CONTRIBUTES TO VIRULENCE [J].

ISAACS, SN ;

KOTWAL, GJ ;

MOSS, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (02) :628-632

← 4 5 6 7 8 9 10 11 12 13 →